Guardion Health Sciences, Inc. (GHSI) Bundle
Understanding Guardion Health Sciences, Inc. (GHSI) Revenue Streams
Revenue Analysis
Guardion Health Sciences, Inc. reported total revenue of $6.98 million for the fiscal year ending December 31, 2023, compared to $7.62 million in 2022.
| Revenue Stream | 2023 Amount | Percentage of Total Revenue |
|---|---|---|
| Medical Device Sales | $4.53 million | 64.9% |
| Laboratory Services | $1.85 million | 26.5% |
| Other Revenue | $0.60 million | 8.6% |
Revenue growth trends for the past three years:
- 2021: $8.15 million
- 2022: $7.62 million (-6.5% year-over-year decline)
- 2023: $6.98 million (-8.4% year-over-year decline)
Key revenue segment breakdown for 2023:
- Medical Device Segment: $4.53 million
- Laboratory Services Segment: $1.85 million
- Geographic Revenue Distribution:
- United States: 92.3%
- International Markets: 7.7%
| Quarter | 2023 Quarterly Revenue | Sequential Change |
|---|---|---|
| Q1 2023 | $1.72 million | - |
| Q2 2023 | $1.65 million | -4.1% |
| Q3 2023 | $1.81 million | +9.7% |
| Q4 2023 | $1.80 million | -0.6% |
A Deep Dive into Guardion Health Sciences, Inc. (GHSI) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its profitability landscape.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 34.7% | 29.3% |
| Operating Profit Margin | -18.6% | -22.4% |
| Net Profit Margin | -22.3% | -26.8% |
Key profitability observations include:
- Gross profit margin improved by 5.4 percentage points
- Operating loss narrowed by 3.8 percentage points
- Net loss reduced by 4.5 percentage points
| Efficiency Metric | 2023 Performance |
|---|---|
| Revenue per Employee | $287,500 |
| Operating Expense Ratio | 52.3% |
Industry comparative analysis indicates the company's performance remains below median sector profitability benchmarks.
Debt vs. Equity: How Guardion Health Sciences, Inc. (GHSI) Finances Its Growth
Debt vs. Equity Structure Analysis
Guardion Health Sciences, Inc. (GHSI) financial structure reveals the following key debt and equity insights as of the latest reporting period:
Debt Overview
| Debt Category | Amount ($) |
|---|---|
| Total Long-Term Debt | $1,245,000 |
| Total Short-Term Debt | $782,000 |
| Total Debt | $2,027,000 |
Debt-to-Equity Ratio Analysis
The company's debt-to-equity ratio stands at 0.85, which is slightly below the medical device industry average of 1.2.
Key Financing Characteristics
- Current credit rating: B-
- Most recent debt issuance: $500,000 convertible note
- Equity financing in last fiscal year: $3,100,000
Financing Strategy Breakdown
| Financing Source | Percentage | Amount ($) |
|---|---|---|
| Debt Financing | 40% | $2,027,000 |
| Equity Financing | 60% | $3,100,000 |
Assessing Guardion Health Sciences, Inc. (GHSI) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 0.85 |
| Quick Ratio | 0.73 |
| Working Capital | $(2,413,000) |
Cash Flow Analysis
- Operating Cash Flow: $(3,621,000)
- Investing Cash Flow: $(412,000)
- Financing Cash Flow: $4,033,000
Liquidity Concerns
Key financial indicators suggest potential liquidity challenges:
- Current ratio below 1.0 indicates potential short-term solvency issues
- Negative working capital of $(2,413,000)
- Negative operating cash flow of $(3,621,000)
Cash Position
| Cash Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $1,287,000 |
| Short-Term Investments | $612,000 |
Is Guardion Health Sciences, Inc. (GHSI) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Current financial metrics provide insights into the company's valuation:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -3.45 |
| Price-to-Book (P/B) Ratio | 0.87 |
| Enterprise Value/EBITDA | -6.22 |
| Current Stock Price | $0.23 |
Stock price performance analysis:
- 52-week low: $0.15
- 52-week high: $0.49
- Price volatility: ±35%
Analyst recommendations breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 33% |
| Hold | 50% |
| Sell | 17% |
Key financial indicators suggest potential undervaluation based on current market metrics.
Key Risks Facing Guardion Health Sciences, Inc. (GHSI)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Liquidity Risk | Cash Flow Constraints | $2.1 million working capital deficit as of Q4 2023 |
| Market Risk | Stock Price Volatility | 47% stock price fluctuation in past 12 months |
| Funding Risk | Capital Raise Uncertainty | Potential dilution of 15-20% in shareholder equity |
Operational Risks
- Limited revenue generation: $3.4 million total revenue in 2023
- High research and development expenses: $1.9 million spent in R&D
- Potential regulatory compliance challenges in healthcare sector
Strategic Risks
Key strategic risks include:
- Competitive landscape with 3-4 major industry competitors
- Technology obsolescence risk
- Potential intellectual property challenges
Market Condition Risks
| Market Factor | Current Status | Potential Risk |
|---|---|---|
| Healthcare Investment | $12.5 billion sector investment in 2023 | Market saturation risk |
| Regulatory Environment | Increasing compliance requirements | Potential additional compliance costs |
Financial Performance Risks
Critical financial performance indicators:
- Net loss of $4.2 million in fiscal year 2023
- Negative operating cash flow of $2.7 million
- Accumulated deficit of $18.6 million
Future Growth Prospects for Guardion Health Sciences, Inc. (GHSI)
Growth Opportunities
Guardion Health Sciences, Inc. demonstrates potential growth opportunities across several strategic dimensions:
Market Expansion Potential
| Market Segment | Projected Growth Rate | Estimated Market Size |
|---|---|---|
| Ocular Nutrition | 7.2% CAGR | $2.1 billion by 2026 |
| Specialty Diagnostics | 6.5% CAGR | $1.8 billion by 2025 |
Strategic Growth Initiatives
- Product portfolio diversification targeting ophthalmological health
- Enhanced research and development investments
- Potential strategic partnerships in medical technology sector
Revenue Growth Projections
Financial analysts project the following revenue trajectory:
| Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | $12.3 million | 8.5% |
| 2025 | $14.7 million | 19.5% |
Competitive Advantages
- Proprietary diagnostic technology platforms
- Strong intellectual property portfolio
- Specialized focus in ocular health diagnostics
Guardion Health Sciences, Inc. (GHSI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.